Role of Histone Deacetylase Inhibitors in the Treatment of Lymphomas and Multiple Myeloma

被引：12

作者：

Zain, Jasmine ^{[1
]}

机构：

[1] NYU Langone Med Ctr, Div Hematol Malignancies & Med Oncol, New York, NY 10016 USA

来源：

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2012年 / 26卷 / 03期

关键词：

Histone deacetylase inhibitors; Lymphoma; Multiple myeloma; Epigenetic therapy; SUBEROYLANILIDE HYDROXAMIC ACID; PERIPHERAL T-CELL; PHASE-II TRIAL; VALPROIC ACID; GENE-EXPRESSION; DEPSIPEPTIDE FR901228; HODGKIN LYMPHOMA; HDAC INHIBITOR; EPIGENETIC THERAPIES; FK228; DEPSIPEPTIDE;

D O I：

10.1016/j.hoc.2012.01.006

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Histone deacetylase inhibitors (HDACI) have allowed pharmacologic manipulation of deregulated genes in cancer cells and have shown single-agent activity against T cell lymphomas, cutaneous T cell lymphomas, mantle cell lymphomas, and Hodgkin disease. The bigger promise of these agents is in enhancing the activity of other targeted therapies. In addition, the effects of HDACI on the immune system and cytokines indicate that HDACI can be useful in the treatment of immune dysfunction underlying tumorigenesis, autoimmune disorders, and graft-versus-host disease. There is also an effort to determine whether class specificity of HDACI has a biologic significance.

引用

页码：671 / +

页数：35

共 50 条

[31] Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma
Richardson, Paul G.
Mitsiades, Constantine S.
Laubach, Jacob P.
Hajek, Roman
Spicka, Ivan
Dimopoulos, Meletios A.
Moreau, Philippe
Siegel, David S.
Jagannath, Sundar
Anderson, Kenneth C.
LEUKEMIA RESEARCH, 2013, 37 (07) : 829 - 837
[32] Role of proteasome inhibitors as treatment of multiple myeloma
Pasquier, Florence
Moreau, Anne-Sophie
Tricot, Sabine
Wemeau, Mathieu
Facon, Thierry
Leleu, Xavier
HEMATOLOGIE, 2006, 12 (01): : 67 - 76
[33] Role of histone deacetylase inhibitors in antitumor therapy
Ameyar-Zazoua, Maya
Harel-Bellan, Annick
BULLETIN DU CANCER, 2006, 93 : 83 - 87
[34] Histone deacetylase inhibitors in T cell lymphomas as a paradigm in cancer therapy
Bates, S. E.
Piekarz, R.
Wright, J.
Fojo, T.
ANNALS OF ONCOLOGY, 2007, 18 : 23 - 23
[35] Thioredoxin in cancer - Role of histone deacetylase inhibitors
Marks, Paul A.
SEMINARS IN CANCER BIOLOGY, 2006, 16 (06) : 436 - 443
[36] PANOBINOSTAT, A PAN-HISTONE DEACETYLASE INHIBITOR: RATIONALE FOR AND APPLICATION TO TREATMENT OF MULTIPLE MYELOMA
Cheng, T.
Grasse, L.
Shah, J.
Chandra, J.
DRUGS OF TODAY, 2015, 51 (08) : 491 - 504
[37] Phase 2 Trial of the Histone Deacetylase Inhibitor Romidepsin for the Treatment of Refractory Multiple Myeloma
Niesvizky, Ruben
Ely, Scott
Mark, Tomer
Aggarwal, Sangeeta
Gabrilove, Janice L.
Wright, John J.
Chen-Kiang, Selina
Sparano, Joseph A.
CANCER, 2011, 117 (02) : 336 - 342
[38] Histone-deacetylase inhibitors for the treatment of cancer
Lindemann, RK
Gabrielli, B
Johnstone, RW
CELL CYCLE, 2004, 3 (06) : 779 - 788
[39] Histone Deacetylase Inhibitors in the Treatment of Hematological Malignancies
Petrella, A.
Fontanella, B.
Carratu, A.
Bizzarro, V.
Rodriquez, M.
Parente, L.
MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2011, 11 (06) : 519 - 527
[40] Histone deacetylase inhibitors for treatment of hepatocellular carcinoma
Danila CORADINI
Annalisa SPERANZA
Acta Pharmacologica Sinica, 2005, (09) : 1025 - 1033

← 1 2 3 4 5 →